论文部分内容阅读
目前自体骨髓移植(ABMT)作为一种积极的治疗手段方兴未艾。不过,对其费用、可能产生的并发症及死亡率要有充分的估计,以权衡在临床上的利弊。应在何时施行ABMT? ABMT的骨髓采集和贮存的最佳时间是在CR的早期,此时从理论上讲,细胞抑制已达到最大限度,而造血干细胞尚未因长期化疗遭到严重损害。选择大剂量细胞抑制剂加ABMT作为强烈治疗时,应考虑到患者用“常规”化疗时的预后因素。另外还要考虑到急性髓细胞白血病(AML)患者获得持久的第2次缓解的机会比ALL患者要少。因此,AML患者在第2次CR期接受大剂量细胞
Autologous bone marrow transplantation (ABMT) is currently in the ascendant as a positive treatment. However, its costs, possible complications and mortality should be fully estimated to weigh the clinical pros and cons. The optimal time for bone marrow harvesting and storage in ABMT ™ ABMT should be at an early stage of CR, when in theory cytostasis has been maximized and hematopoietic stem cells have not been severely damaged by long-term chemotherapy. The choice of high-dose cytostatics plus ABMT for intensive care should take into account the prognostic factors of patients taking “conventional” chemotherapy. Also consider that patients with acute myeloid leukemia (AML) have less chance of lasting second remission than those with ALL. Therefore, patients with AML received high doses of cells during the second CR